X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company intends to use the net proceeds for research and development of its pipeline of Alpaca-derived nanosized antibodies (NanoAbs) targeting SARS-CoV-2 variants.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 04, 2024
Details:
The company intends to use the net proceeds for research and development of its pipeline of Alpaca-derived nanosized antibodies (NanoAbs) targeting SARS-CoV-2 variants.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 29, 2023
Details:
Scinai Immunotherapeutics is developing a IL-17A Inhibitor antibody drug candidate, which is currently being evaluated for the treatment of patients with mild to moderate plaque psoriasis.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
The Company will use the proceeds for research and development of its pipeline, including NanoAb-based inflammation and immunology biological therapeutics for autoimmune and infectious diseases such as psoriasis, psoriatic arthritis, asthma, wet AMD and COVID-19.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2023
Details:
The Company will use the proceeds for research and development of its pipeline, including NanoAb-based inflammation and immunology biological therapeutics for autoimmune and infectious diseases such as psoriasis, psoriatic arthritis, asthma, wet AMD and COVID-19.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 15, 2023
Details:
NanoAbs (alpaca-derived nanosized antibody) also known as VHH-antibodies, exhibit potential as biobetter therapies for a wide range of diseases. Scinai is developing NanoAbs addressing diseases with large unmet medical needs and attractive commercial opportunities, such as psoriasis.
Lead Product(s): Alpaca-derived Nanosized Antibody
Therapeutic Area: Dermatology Product Name: NanoAbs
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
The agreement aims to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.
Lead Product(s): VHH-Antibody
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Max Planck
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 05, 2023
Details:
NanoAbs (alpaca-derived nanosized antibodies), exhibit potential for superior therapies for a wide range of diseases. NanoAb is currently studied for the treatment of COVID-19, exhibits significant competitive advantages over existing mAbs and oral therapies.
Lead Product(s): Alpaca-derived Nanosized Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: NanoAbs
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
NanoAbs ia an alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies*, exhibit potential for superior therapies for a wide range of diseases. Product is being developed for treatment of COVID-19.
Lead Product(s): NanoAb COVID-19 Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
Alpaca-derived nanosized antibodies, also known as VHH-antibodies, exhibit potential for superior therapies for a wide range of diseases. NanoAb, for treatment of COVID-19, exhibits significant competitive advantages over existing mAbs and oral therapies.
Lead Product(s): Alpaca-derived Nanosized Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
